Journal List > Korean Diabetes J > v.32(2) > 1002210

Kim: Letter: Prevalence and Clinical Characteristics of Aspirin Resistance in the Patients with Type 2 Diabetes

References

1. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J. 2007. 28:1925–1927.
crossref
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy fot prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002. 324:71–86.
3. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project(PPP) trial. Diabetes Care. 2003. 26:3264–3272.
4. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, Gawaz M, Dietz R, Bocksch W. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005. 42:99–103.
crossref
5. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Gildfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol. 2006. 97:567–570.
crossref
7. Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep. 2005. 57(Suppl):42–58.
TOOLS
Similar articles